Logos Global Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Logos Global Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-180,000	Closed	-$6.84M	–	51
2022 Q4	$6.84M	Buy	+180,000	New	+$6.19M	0.8%	31
2020 Q3	–	Sell	-200,000	Closed	-$31.2M	–	64
2020 Q2	$31.2M	Buy	200,000 +117,708	+143%	+$17.9M	6.24%	2
2020 Q1	$11.9M	Buy	82,292 +26,592	+48%	+$5.13M	4.52%	6
2019 Q4	$11.4M	Buy	+55,700	New	+$10.2M	2.81%	15

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Logos Global Management's RETA Position: Q1 2023 in Review

Logos Global Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 180,000 shares — an estimated $6.84M sold.

Logos Global Management first reported a position in RETA in Q4 2019 and held it in 4 quarters. The position peaked at $31.2M in Q2 2020. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Logos Global Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Logos Global Management sold 180,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $6.84M.
Logos Global Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 4 quarters.
Logos Global Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $31.2M in Q2 2020.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Logos Global Management's 13F filing for Q1 2023, filed 15 May 2023.